PHB2 and breast carcinoma: In particular, the discovery that stERAP enables reactivation of the innate tumor-suppressive activity of PHB2 based on this molecular mechanism may lead to therapeutics that greatly contribute to the treatment of refractory breast cancer without impairing the quality of life of patients.